KLOW Blend

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

The KLOW Blend has no FDA regulatory designation as a combination product. All four individual components (BPC-157, TB-500, KPV, and GHK-Cu) were listed in the FDA Category 2 bulk drug substances list under Section 503A. BPC-157, TB-500, and KPV were among the peptides removed from Category 2 effective approximately April 22–23, 2026, following HHS direction; all three are scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23–24, 2026 (docket FDA-2025-N-6895). GHK-Cu (injectable formulations) was also removed from Category 2 in April 2026, with non-injectable GHK-Cu under separate review. Removal from Category 2 does not confer Category 1 status or authorize compounding; formal notice-and-comment rulemaking following PCAC review is still required. None of the four components is FDA-approved as a drug. The blend is a research-use-only chemical with no authorized human use.

Transparent blend · bci-1.0 · never paid-placement

Primary name

KLOW Blend

Origin

KLOW Blend is a vendor-formulated co-lyophilized combination of four individually characterized research peptides: BPC-157 (a synthetic 15-amino-acid sequence derived from human gastric juice protein BPC), TB-500 (a synthetic peptide corresponding to the actin-binding domain fragment, residues 17–23, of Thymosin Beta-4), KPV (the tripeptide lysyl-prolyl-valine, representing the C-terminal residues 11–13 of alpha-melanocyte-stimulating hormone), and GHK-Cu (the endogenous tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II) ions, first isolated from human plasma in 1973). The blend has no independent regulatory designation, no single CAS number, and no PubChem entry; its identity is fully defined by its four component peptides. The name 'KLOW' is a vendor-coined designation with no formal scientific nomenclature.

Appearance

White to off-white lyophilized powder (co-lyophilized blend); GHK-Cu component may impart a faint blue tint at higher concentrations upon reconstitution due to copper(II) chelation

Solubility

Reconstitutes in sterile water or bacteriostatic water; all four components are …

Sequence not available in current seed.

Stability: Each component has distinct stability profiles. GHK-Cu is susceptible to copper oxidation and may degrade at elevated temperatures or in the presence of oxidizi

Vial sizes

80 mg

Purity grades

research grade / ≥98% HPLC (vendor-stated)

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Synthetic 15-amino-acid gastric pentadecapeptide studied in animal models for tissue repair, angiogenesis, and GI protection.

BPC-157 has been shown in rodent and cell-culture studies to upregulate vascular endothelial growth factor receptor 2 (VEGFR2) and activate downstream Akt–eNOS signaling, promoting endothelial nitric oxide production and new vessel formation. The peptide also engages the focal adhesion kinase (FAK)–paxillin pathway, facilitating endothelial cell migration during angiogenesis. Additional preclinical data indicate modulation of nitric oxide synthesis more broadly, with context-dependent protective effects against cytotoxic NO excess while preserving physiological NO-mediated functions. These converging angiogenic and cytoprotective pathways are proposed to underlie observations of accelerated wound closure, tendon reattachment, and gastrointestinal mucosal recovery in animal injury models.

Molar mass

1419.5 g/mol

Synthetic 9-amino-acid fragment (Ac-LKKTETQ) of thymosin beta-4 studied in animal models for tissue repair, cell migration, and angiogenesis.

TB-500 binds monomeric G-actin through the same LKKT(X)E motif present in the full thymosin beta-4 protein, sequestering free actin monomers and preventing their incorporation into filamentous F-actin networks; this shifts the intracellular actin equilibrium in a manner that facilitates lamellipodia formation and directed cell migration. Concurrently, the peptide activates integrin-linked kinase (ILK) signaling, promoting downstream phosphorylation events that stimulate keratinocyte and endothelial cell motility. In rodent wound and ischemia models, these effects are accompanied by upregulation of vascular endothelial growth factor (VEGF) and accelerated capillary sprouting, suggesting a secondary pro-angiogenic axis. NF-kB pathway modulation has also been reported in preclinical inflammation models, though the mechanistic hierarchy relative to actin sequestration remains unresolved.

Molar mass

889.0 g/mol

C-terminal tripeptide of α-MSH (Lys-Pro-Val) that suppresses NF-κB-driven inflammation and is absorbed by intestinal PepT1 transporters in preclinical models.

KPV inhibits the NF-κB signaling pathway, blocking nuclear translocation of the p65 subunit and reducing downstream transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Unlike the full α-MSH molecule, KPV's anti-inflammatory activity appears to be partially independent of classical melanocortin receptor engagement, suggesting intracellular or alternative receptor mechanisms that remain under investigation. In intestinal epithelia, KPV is actively transported into cells via the proton-coupled oligopeptide transporter PepT1 (SLC15A1), which is upregulated in inflamed colonic mucosa, potentially creating preferential delivery to inflamed sites. Additional activity in keratinocytes and macrophages involves suppression of MAP-kinase signaling cascades alongside NF-κB, consistent with broad attenuation of innate immune activation.

Molar mass

192.21 g/mol

Endogenous copper-chelating tripeptide that modulates collagen remodeling, fibroblast activity, and wound healing; researched topically and in injectable form.

GHK-Cu binds copper(II) with high affinity and delivers it to cells involved in tissue repair. In fibroblast and keratinocyte models, the complex upregulates genes encoding collagen I and III, elastin, decorin, and glycosaminoglycans while simultaneously modulating matrix metalloproteinase activity to favor balanced matrix remodeling over excessive degradation or fibrosis. GHK-Cu also stimulates angiogenesis and exhibits antioxidant activity partly through superoxide dismutase (SOD)-like copper chemistry, and has been reported in preclinical studies to suppress pro-inflammatory NF-κB signaling pathways.

Molar mass

400.90 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• Each of the four components contributes a mechanistically distinct but complementary pathway relevant to tissue repair and inflammation resolution
• BPC-157 activates the VEGFR2–Akt–eNOS axis and the FAK–paxillin pathway, promoting angiogenesis and fibroblast migration in preclinical injury models while also modulating nitric oxide balance in a bidirectional manner that counteracts free-radical formation
• TB-500 sequesters G-actin monomers via its LKKTETQ motif, maintaining a mobilizable cytoskeletal pool that facilitates keratinocyte, fibroblast, and endothelial cell migration in response to injury signals
• KPV enters cells via the PepT1 oligopeptide transporter and accumulates in the nucleus, where it physically inhibits NF-κB and MAPK inflammatory signaling independently of melanocortin receptor binding, thereby reducing TNF-α, IL-1β, and IL-6 secretion

Pharmacokinetics (ADME)

Half-life

BPC-157: ~5–15 min IV (rodent); TB-500: hours subcutaneous (rodent, with active C-terminal metabolites reported); KPV: minutes to hours systemic, carrier-dependent (animal data only); GHK-Cu: minutes systemic (animal models). Blend-specific PK data absent.

Clearance

All components subject to proteolytic degradation; GHK-Cu also undergoes copper dissociation under physiological pH conditions. KPV oral bioavailability is enhanced by PepT1-mediated intestinal uptake in rodent models; parenteral clearance is not formally characterized. No blend-level clearance data are available.

PK–PD note: A PK–PD disconnect has been described for BPC-157 individually (rapid plasma clearance with prolonged downstream signaling). Active TB-500 metabolites such as Ac-LKKTE retain wound-healing activity in…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025 Jul 31. PMID 40756949; PMC12313605. (36 studies: 35 preclinical, 1 retrospective clinical) — component-level, not KLOW blend. — Anchoring systematic review for the BPC-157 component only; not a review of the KLOW blend as a combined product.
• Mortazavi SM, et al. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2024. PMID 39963574; PMC11830136. — component-level (GHK-Cu). — Review of GHK (copper-binding tripeptide) component; topical/cosmetic focus, not the KLOW blend.
• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. PMC12446177. — component-level (BPC-157). — Narrative review noting robust preclinical effects but minimal human data for BPC-157 component.

No registered human trials found for this compound.

Status

No registered trials found

Summary (literature)

No safety data exist for the KLOW Blend as a combined four-component formulation. Individual component safety profiles, all derived exclusively from preclinical research, must be inferred separately. BPC-157 has shown a generally favorable tolerability profile in rodent and canin…

WADA status

Two of four components are prohibited by WADA. BPC-157 is listed under S0 (Non-Approved Substances), prohibited at all times. TB-500 (Thymosin Beta-4 analog) is…

Dominant research route: Subcutaneous (SC) — community/physician-anecdotal; no formal PK study of the blend

No formal PK study of the KLOW blend as a unit; described in physician-supervised post-surgical protocols (Agullo, MD) and aggregate community use of reconstituted lyophilized blend

Bioavailability: Sold as sterile lyophilized powder for reconstitution; no blend-level bioavailability, Cmax, or t½ data published. Component GHK-Cu described as released into circulation when administered subcutaneously versus topical stratum-corneum penetration

Dominant community/clinical-anecdotal route. A board-certified plastic surgeon (Agullo) describes prescribing KLOW (GHK-Cu+BPC-157+TB-500+KPV) to surgical patients with subcutaneous GHK-Cu administration; this is physician-reported use, not a controlled trial of the blend

Component-level preclinical only: BPC-157 stable in human gastric juice >24 h and orally active in rodent GI models; KPV transported by PepT1 and orally active in murine DSS/TNBS colitis models. No oral study of the KLOW blend as a unit

Bioavailability: Unprotected KPV oral bioavailability is poor due to peptidase digestion (PepT1-targeted/enteric formulations studied); BPC-157 retains structural integrity in simulated gastric fluid pH 2. GHK-Cu and TB-500 oral stability not established for the blend

Oral-stability evidence is component-specific and preclinical; it does not establish oral absorption or bioavailability of the four-component blend. KPV oral activity is gut-tissue-targeted (PepT1), not systemic

Component-level only: GHK-Cu (copper peptide) studied in topical cosmetic/dermal formulations for stratum-corneum penetration to dermis; no topical study of the KLOW blend

Bioavailability: Topical GHK-Cu must penetrate stratum-corneum to access dermis; per Agullo, subcutaneous GHK-Cu bypasses this barrier. No blend-level topical data

Topical route evidence is limited to the GHK-Cu component; BPC-157, TB-500, and KPV topical delivery within the blend is not studied

Component-level preclinical: BPC-157 reported bioavailable in rodent models when administered IM or IV; no IM study of the KLOW blend

Bioavailability: BPC-157 stable at room temperature and bioavailable IM/IV in rodent models per Wikipedia summary of primary literature; blend-level IM data absent

IM evidence is BPC-157-component-only and preclinical; not a studied route for the four-peptide blend

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $0.750 · median $0.858 · p75 $1.74 · 12 researched vendors

Legit, COA-backed band: $0.570–$2.00/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$6

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Janoshik Analytical reports for KLOW 80mg (Panda Peptides batch) show 'Multi-component verified' status with an endotoxin level of 6.708 EU/Vial. Individual component purities from the same lab's batch reports: BPC-157 99.557% HPLC, TB-500 98.48% HPLC, GHK-Cu 99.925% HPLC, KPV 99.22% HPLC. Multiple vendors claim 99%+ purity for KLOW Blend.

Independent labs cited for this compound

No FDA recalls or market withdrawals found specifically targeting KLOW Blend or any product sold under the KLOW name. None found.

Buyer red-flag checklist

• No FDA-approved drug application exists for KLOW Blend or any of its four components (BPC-157, TB-500, GHK-Cu, KPV)
• RUO label does not exempt products from FDA Import Alert 66-41 detention without physical examination
• BPC-157 and TB-500 were classified as FDA Category 2 'Substances with Safety Concerns' (Sept 2023); reclassification to Category 1 announced April 2026 but does not confer FDA approval
• BPC-157 and TB-500 are prohibited under the WADA Prohibited List (S0 Unapproved Substances)
• No published randomized controlled trial exists for the KLOW Blend as a whole; evidence is limited to individual component preclinical/clinical studies
• Endotoxin level of 6.708 EU/Vial reported in one Janoshik-tested KLOW 80mg batch (Panda Peptides), higher than most single-peptide batches from the same vendor (typically <3 EU/Vial)
• Blend's fixed component ratio may underdose individual peptides relative to standalone research dosing; no validated dosing for the combination
• Multiple vendors market KLOW with therapeutic/disease claims despite lack of FDA approval, creating misbranding risk under FD&C Act Section 502

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No aggregate independent lab data quantifying underdosing prevalence specifically for KLOW Blend was found. Janoshik's report for KLOW 80mg lists 'Multi-component verified' rather than a single purity percentage, and does not publicly quantify each component's mass within the blend. Community observations note the blend's fixed ratio may underdose individual components (e.g., TB-4) relative to standalone research protocols, but this reflects formulation design rather than confirmed underdosing.

• FDA Import Alert 66-41 ('Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.') authorizes DWPE of unapproved new drug peptide imports at the border. Published 06/24/2026, last revised 05/19/2026. A 'Research Use Only' label does not by itself create an importation exemption; FDA evaluates actual marketed and intended use. KLOW Blend and its components have no FDA-approved drug application.66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

KLOW Blend is not a named substance on the WADA Prohibited List. However, two of its four component peptides are prohibited: BPC-157 is prohibited under S0 (Non-Approved Substances) at all times; TB-500 (thymosin beta-4 and its derivatives) is prohibited under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) at all times. KPV is not a named WADA-prohibited substance. GHK-Cu is not explicitly named on the WADA Prohibited List. Use of the KLOW Blend by athletes subject to WADA/USADA testing would constitute an anti-doping rule violation due to the presence of BPC-157 and TB-500.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Vendor-affiliated subreddits (e.g. ParamountPeptide, Ameano_Peptides, USPeptides) appear to seed promotional content
• Anecdotal self-reporting without controls or medical supervision
• Concurrent supplement / peptide stacking confounds attribution of effects
• pH-instability claim originated from a chiropractor (not an MD/PhD), disputed by community
• New-account spam filtering noted on multiple subreddits, suggesting astroturfing risk

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

RUO four-peptide blend of BPC-157, TB-500, KPV, and GHK-Cu studied preclinically for convergent tissue repair, anti-inflammatory, and ECM remodeling pathways. Approximately 0 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Research Use Only; blend not independently regulated. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet